Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NM-6603 by Nucmito for Lung Cancer: Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Lung Cancer. According to GlobalData, Phase I...
NM-6603 by Nucmito for Colorectal Cancer: Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
NM-6603 by Nucmito for Cervical Cancer: Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
NM-6603 by Nucmito for Melanoma: Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
NM-6603 by Nucmito for Liver Cancer: Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Liver Cancer. According to GlobalData, Phase I...
NM-6603 by Nucmito for Pancreatic Cancer: Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
NM-6603 by Nucmito for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
NM-6603 is under clinical development by Nucmito and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...